CLASS ACTION: Kessler Topaz Meltzer & Check, LLP Reminds Natera, Inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Losses over $250,000 to Contact the FirmNewsfile Corp • 05/02/22
INVESTOR ALERT: Natera, Inc. Investors with Substantial Losses Have Opportunity to Lead Natera Class Action Lawsuit - NTRAPRNewsWire • 04/30/22
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm's Attorneys, Deadline Established in Securities Fraud Class ActionNewsfile Corp • 04/30/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Natera, Inc. (NTRA) InvestorsBusiness Wire • 04/29/22
NATERA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Natera, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 04/29/22
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Natera, Inc. (NTRA) to Contact Firm's Attorneys, Securities Fraud Class Action FiledNewsfile Corp • 04/28/22
NATERA, INC. (NASDAQ: NTRA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Natera, Inc. (NASDAQ: NTRA)PRNewsWire • 04/28/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Natera, Inc. (NTRA) InvestorsBusiness Wire • 04/28/22
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Natera, Inc. (NTRA)Business Wire • 04/28/22
Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Natera, Inc.Business Wire • 04/28/22
Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD)PRNewsWire • 04/26/22
Large Real-World Study with Renasight Genetic Test Highlights High Diagnostic Yield for Patients with Chronic Kidney DiseasePRNewsWire • 04/19/22
Multi-Site Clinical Validation of Prospera Heart Test Demonstrates Outstanding Performance in Assessing Heart Transplant RejectionPRNewsWire • 04/13/22
Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual MeetingPRNewsWire • 04/11/22
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Natera, Inc. (NTRA) For Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm's AttorneysNewsfile Corp • 04/07/22
Natera Publishes VALID Study Results for Prospera Lung dd-cfDNA Transplant Rejection Assessment TestPRNewsWire • 04/07/22
NTRA LOSS ALERT: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Natera, Inc. Investors with Losses to Inquire About Class Action Investigation - NTRANewsfile Corp • 04/06/22
Natera Announces Publication Highlighting Importance of Testing Total cfDNA when Monitoring Kidney Transplant Patients with COVID-19 InfectionPRNewsWire • 04/01/22
Natera, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmNewsfile Corp • 03/31/22
Natera Listed as One of World's Most Innovative Health Companies by Fast CompanyPRNewsWire • 03/28/22
NTRA INVESTIGATION: Hagens Berman, National Trial Attorneys, Investigating Natera, Inc. (NTRA) For Possible Securities Law Violations, Investors With Significant Losses Encouraged to Contact FirmNewsfile Corp • 03/23/22
